Skip to main content
    G

    GE HealthCare Technologies Inc. (GEHC)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $82.96
    -0.06 (-0.07%)

    Market Cap: $37.54B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    GE HealthCare Technologies Inc. (GEHC) Earnings: Report Dates and Results

    Updated Oct 28, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    GE HealthCare Technologies (GEHC) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, GE HealthCare Technologies reported EPS of $1.34, above the $1.21 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    88%(14/16)
    Avg Surprise
    +7.91%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$1.59
    Range$1.50 - $1.68
    21 analysts
    Revenue Consensus
    $6.04B
    Range$5.71B - $6.28B
    20 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus$1.11
    Range$0.99 - $1.25
    12 analysts
    EPS Estimate DriftChange to current
    90d ago$1.13-1.7%
    60d ago$1.13-1.7%
    30d ago$1.13-1.5%
    7d ago$1.12-0.3%
    Current$1.11
    Revenue Consensus
    $5.37B
    Range$5.34B - $5.39B
    9 analysts

    Next Report

    GEHC has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 10.4% above the $1.44 reported for the quarter ended Dec 31, 2025.

    GEHC Earnings Call

    The latest GEHC earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 16 quarters below that had an estimate, GEHC beat 14 and missed 2. Revenue for the quarter ended Sep 30, 2026 was $5.51B, up 7.2% from $5.14B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.34$1.21$1.16 - $1.25+10.74%Beat+25.2%181 up, 0 downOct 28, 2026$5.51B
    Jun 30, 2026$1.13$1.04$1.01 - $1.07+8.65%Beat+6.6%140 up, 14 downJul 29, 2026$5.29B
    Mar 31, 2026$0.99$1.05$0.96 - $1.07-5.71%Miss-2.0%152 up, 1 downApr 29, 2026$5.13B
    Dec 31, 2025$1.44$1.40$1.20 - $1.46+2.86%Beat-8.3%161 up, 0 downFeb 4, 2026$5.70B
    Sep 30, 2025$1.07$1.05$0.94 - $1.11+1.90%Beat-6.1%151 up, 1 downOct 29, 2025$5.14B
    Jun 30, 2025$1.06$0.92$0.85 - $0.96+15.22%Beat+6.0%151 up, 0 downJul 30, 2025$5.01B
    Mar 31, 2025$1.01$0.91$0.90 - $0.93+10.99%Beat+12.2%131 up, 1 downApr 30, 2025$4.78B
    Dec 31, 2024$1.57$1.26$1.22 - $1.30+24.60%Beat+33.1%141 up, 0 downFeb 13, 2025$5.32B
    Sep 30, 2024$1.14$1.05$1.00 - $1.10+8.57%Beat+15.2%142 up, 1 downOct 30, 2024$4.86B
    Jun 30, 2024$1.00$0.98$0.93 - $1.02+2.04%Beat+8.7%122 up, 0 downJul 31, 2024$4.84B
    Mar 31, 2024$0.90$0.91$0.87 - $0.96-1.10%Miss+5.9%111 up, 0 downApr 30, 2024$4.65B
    Dec 31, 2023$1.18$1.07$1.04 - $1.09+10.28%Beat-2.5%110 up, 0 downFeb 6, 2024$5.21B
    Sep 30, 2023$0.99$0.90$0.87 - $0.92+10.00%Beat-10.8%100 up, 0 downOct 31, 2023$4.82B
    Jun 30, 2023$0.92$0.87$0.81 - $0.93+5.75%Beat-51.6%70 up, 0 downJul 25, 2023$4.82B
    Mar 31, 2023$0.85$0.79$0.77 - $0.81+7.59%BeatN/A40 up, 0 downApr 25, 2023$4.71B
    Dec 31, 2022$1.21$1.06N/A+14.15%BeatN/AN/AN/AJan 30, 2023$4.94B
    Sep 30, 2022$1.11N/AN/AN/AN/AN/AN/AN/ADec 8, 2022$4.58B
    Jun 30, 2022$1.90N/AN/AN/AN/AN/AN/AN/ASep 13, 2022$4.48B
    Last 18 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $4.58, within 4 cents of the year before. It was $4.22 for the year ended Dec 31, 2022, the oldest of the 4 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$4.58N/A
    Dec 31, 2024$4.61+17.0%
    Dec 31, 2023$3.94-6.6%
    Dec 31, 2022$4.22N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,000 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,02314
    2026Q2Jun 30, 20268,78812
    2026Q1Mar 31, 20267,36913
    2025Q4Dec 31, 20252,0345
    2025Q3Sep 30, 20258,31713
    2025Q2Jun 30, 20258,59111
    2025Q1Mar 31, 20258,22412
    2024Q4Dec 31, 20248,39212

    2026Q3 Earnings Call

    Opening remarks

    Carolynne Borders Head of Investor Relations Thanks, operator. Good morning, and welcome to GE Healthcare's Third Quarter 2026 Earnings Call. I am joined by our President and CEO, Peter J. Arduini; CFO, William K. Grogan; and Controller and Chief Accounting Officer, George Andrew Newcomb. Our conference call remarks will include both GAAP and non-GAAP financial results. Reconciliations between GAAP and non-GAAP measures can be found in today's press release and in the presentation slides available on our website. During this call, we will make forward-looking statements about our performance. These statements are based on how we see things today. As described in our SEC filings, actual results may differ materially due to risks and uncertainties. With that, I will hand the call over to Peter.

    Peter J. Arduini President and CEO Thanks, Carolynne. Good morning, and thank you for joining us today. Before I review highlights from the quarter, I want to take a moment to welcome Bill. He brings tremendous experience and a strong track record, and I am looking forward to partnering with him as we execute against our strategy and deliver on our priorities. Looking at our third quarter results on slide 3, we delivered strong top-line growth and margin expansion across all segments. Broad-based demand in advanced imaging solutions and pharmaceutical diagnostics supported healthy orders, book-to-bill, and backlog. Heartbeat is strengthening how we run the company and helping our teams deliver on commercial and operational simplification. A great example of performance driven by Heartbeat this quarter is Patient Care Solutions. The team identified root causes of prior supply challenges and implemented standard work and daily management to drive ongoing improvements. This drove backlog conversion and stronger operational performance. Taken together, momentum in our business has enabled us to raise our full-year 2026 guidance, which Bill will cover later in the call. Turning to slide 4, let's look at how we are advancing our growth strategy. We reached key regulatory milestones in the quarter on two imaging platforms with market-differentiating features. We received CE marking for Photonova Spectra, our photon-counting CT system, and Starguide GX, our SPECT/CT system, is pending FDA clearance. This broadens our ability to commercialize in more markets. We also expanded our ultrasound platforms in cardiovascular, women's health, and general imaging, with the launch of several new products to meet the growing demand for noninvasive imaging. We continue to see general imaging ultrasound as an attractive market where we are investing for the long term. With growing demand, staffing constraints, and more distributed care, ultrasound's versatility across a broad range of exams is increasingly valuable. PDx delivered another excellent quarter with growth in contrast media and radiopharmaceuticals, including proprietary tracers aligned to disease states.

    Frequently Asked Questions About GEHC

    When is GE HealthCare Technologies's next earnings date?

    GE HealthCare Technologies's next earnings report is expected for Feb 8, 2027.

    Did GEHC beat earnings estimates last quarter?

    Yes. GE HealthCare Technologies reported EPS of $1.34 for the quarter ended Sep 30, 2026, above the $1.21 estimate, a 10.74% surprise.

    What EPS do analysts expect from GEHC next quarter?

    The consensus EPS estimate for GE HealthCare Technologies for the quarter ending Dec 31, 2026 is $1.59 from 21 analysts, with estimates from $1.50 to $1.68.

    How often does GEHC beat earnings estimates?

    GE HealthCare Technologies beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +8.66%.